WO2006127360A3 - Lipid construct for delivery of interferon to a mammal - Google Patents

Lipid construct for delivery of interferon to a mammal Download PDF

Info

Publication number
WO2006127360A3
WO2006127360A3 PCT/US2006/019118 US2006019118W WO2006127360A3 WO 2006127360 A3 WO2006127360 A3 WO 2006127360A3 US 2006019118 W US2006019118 W US 2006019118W WO 2006127360 A3 WO2006127360 A3 WO 2006127360A3
Authority
WO
WIPO (PCT)
Prior art keywords
interferon
composition
lipid construct
mammal
delivery
Prior art date
Application number
PCT/US2006/019118
Other languages
French (fr)
Other versions
WO2006127360A2 (en
Inventor
John R Lau
W Blair Geho
Original Assignee
Sdg Inc
John R Lau
W Blair Geho
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US11/384,575 external-priority patent/US20070218117A1/en
Application filed by Sdg Inc, John R Lau, W Blair Geho filed Critical Sdg Inc
Priority to EP06770516A priority Critical patent/EP1883395A4/en
Priority to JP2008513540A priority patent/JP2008542270A/en
Priority to CA002609376A priority patent/CA2609376A1/en
Priority to AU2006249479A priority patent/AU2006249479A1/en
Priority to US11/920,891 priority patent/US20100129428A1/en
Publication of WO2006127360A2 publication Critical patent/WO2006127360A2/en
Publication of WO2006127360A3 publication Critical patent/WO2006127360A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A61K38/212—IFN-alpha
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A61K38/215—IFN-beta
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A61K38/217—IFN-gamma
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/543—Lipids, e.g. triglycerides; Polyamines, e.g. spermine or spermidine
    • A61K47/544—Phospholipids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Liposomes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Abstract

The instant invention is drawn to a hepatocyte targeted composition comprising interferon associated with a lipid construct comprising amphipathic lipid molecules and receptor binding molecule. The composition can comprise a mixture of free interferon and interferon associated with the complex. The composition can be modified to protect interferon and the complex from degradation. The invention also includes methods for the manufacture of the composition and loading interferon into the composition and recycling various components of the composition and methods of treating individuals infected with the hepatitis C and other hepatitis viruses.
PCT/US2006/019118 2005-05-23 2006-05-16 Lipid construct for delivery of interferon to a mammal WO2006127360A2 (en)

Priority Applications (5)

Application Number Priority Date Filing Date Title
EP06770516A EP1883395A4 (en) 2005-05-23 2006-05-16 Lipid construct for delivery of interferon to a mammal
JP2008513540A JP2008542270A (en) 2005-05-23 2006-05-16 Lipid constructs for delivering interferon to mammals
CA002609376A CA2609376A1 (en) 2005-05-23 2006-05-16 Lipid construct for delivery of interferon to a mammal
AU2006249479A AU2006249479A1 (en) 2005-05-23 2006-05-16 Lipid construct for delivery of interferon to a mammal
US11/920,891 US20100129428A1 (en) 2005-05-23 2006-05-16 Supra molecular construct for delivery of interferon to a mammal

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US68387805P 2005-05-23 2005-05-23
US60/683,878 2005-05-23
US11/384,575 US20070218117A1 (en) 2006-03-20 2006-03-20 Supra molecular construct for delivery of interferon to a mammal
US11/384,575 2006-03-20

Publications (2)

Publication Number Publication Date
WO2006127360A2 WO2006127360A2 (en) 2006-11-30
WO2006127360A3 true WO2006127360A3 (en) 2008-01-10

Family

ID=37452604

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2006/019118 WO2006127360A2 (en) 2005-05-23 2006-05-16 Lipid construct for delivery of interferon to a mammal

Country Status (6)

Country Link
EP (1) EP1883395A4 (en)
JP (1) JP2008542270A (en)
KR (1) KR20080042045A (en)
AU (1) AU2006249479A1 (en)
CA (1) CA2609376A1 (en)
WO (1) WO2006127360A2 (en)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BRPI0814737B8 (en) * 2007-08-03 2021-05-25 Biotron Ltd composition for the treatment of hcv, and use of a composition
US8962015B2 (en) * 2007-09-28 2015-02-24 Sdg, Inc. Orally bioavailable lipid-based constructs
EP2235199A1 (en) * 2007-12-17 2010-10-06 Lux Innovate Limited Compositions and methods for maintenance of fluid conducting and containment systems
CA2890238A1 (en) 2012-11-02 2014-05-08 Merck Patent Gmbh Method of reducing adverse effects in a cancer patient undergoing treatment with a mek inhibitor
CN111690539A (en) * 2020-07-07 2020-09-22 安徽农业大学 Screening and application of high-efficiency straw cellulose decomposition bacteria
MX2023006189A (en) * 2020-11-27 2023-07-04 D&D Pharmatech Inc Oral formulation of biologically active material conjugate having biotin moiety, fatty acid moiety, or combination thereof coupled thereto.
IL303229A (en) * 2020-11-27 2023-07-01 D& D Pharmatech Inc Biologically active material conjugate having biotin moiety, fatty acid moiety, or combination thereof coupled thereto

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4603044A (en) * 1983-01-06 1986-07-29 Technology Unlimited, Inc. Hepatocyte Directed Vesicle delivery system

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9426484D0 (en) * 1994-12-08 1995-03-08 Ciba Geigy Ag Compositions
TW520297B (en) * 1996-10-11 2003-02-11 Sequus Pharm Inc Fusogenic liposome composition and method

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4603044A (en) * 1983-01-06 1986-07-29 Technology Unlimited, Inc. Hepatocyte Directed Vesicle delivery system

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
FOSTER G.R.: "Pegylated Interferon with Ribavirin Therapy for Chronic Infection with the Hepatitis C Virus", EXP. OPIN. PHARMACOTHER., vol. 4, no. 5, 2003, pages 685 - 691, XP009020353 *
See also references of EP1883395A4 *

Also Published As

Publication number Publication date
KR20080042045A (en) 2008-05-14
EP1883395A2 (en) 2008-02-06
JP2008542270A (en) 2008-11-27
CA2609376A1 (en) 2006-11-30
AU2006249479A1 (en) 2006-11-30
EP1883395A4 (en) 2012-07-04
WO2006127360A2 (en) 2006-11-30

Similar Documents

Publication Publication Date Title
WO2006127360A3 (en) Lipid construct for delivery of interferon to a mammal
WO2006127361A3 (en) Lipid construct for delivery of insulin to a mammal
Huang Preclinical and clinical advances of GalNAc-decorated nucleic acid therapeutics
WO2006074346A3 (en) RNAi MODULATION OF RSV AND THERAPEUTIC USES THEREOF
WO2009039248A3 (en) Methods of treating a flaviviridae family viral infection and compositions for treating a flaviviridae family viral infection
EP2099825A4 (en) Recombinant antibodies against hepatitis c virus and methods of obtaining and using same
IL195025A (en) Cyclopropyl fused indolobenzazepine derivatives and pharmaceutical compositions comprising the same as anti-hcv medicament
WO2007092888A3 (en) Hcv ns5b inhibitors
MX2010008650A (en) Hepatitis c virus inhibitors.
WO2007140200A3 (en) Cyclopropyl fused indolobenzazepine hcv ns5b inhibitors
MX2010002557A (en) Polyethylene glycol modified interferon alpha 2b and preparation method and applicatioins thereof.
WO2007140254A3 (en) Cyclopropyl fused indolobenzazepine hcv ns5b inhibitors
WO2010047830A3 (en) Agents for hcv treatment
WO2006066079A3 (en) Pyridazinone compounds
WO2008133722A3 (en) Anti human sclerostin antibodies
NO20090438L (en) Hepatitis C virus inhibitors
WO2010075376A3 (en) Anti-viral compounds
WO2007137237A3 (en) Treatment of protein misfolding
WO2008051689A3 (en) Nitric oxide-blocked cross-linked tetrameric hemoglobin
EA201190048A1 (en) ANALOGUE GLUACAGONA
IL196815A0 (en) Hepatitis c virus inhibitors
TWI366602B (en) N protein mutants of porcine reproductive and respiratory syndrome virus
IL200432A (en) Human antibodies against hepatitis c virus (hcv) and uses thereof
CY1112699T1 (en) HCV NS5B CYCLOPROPYPLE CYCLONE CONSOLIDATED INDOLOBENZAZEPIN TYPE INSPECTIONS
WO2008083327A3 (en) Enrichment through heteroduplexed molecules

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 200680026865.9

Country of ref document: CN

121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 2006249479

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 8967/DELNP/2007

Country of ref document: IN

ENP Entry into the national phase

Ref document number: 2609376

Country of ref document: CA

Ref document number: 2008513540

Country of ref document: JP

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: MX/a/2007/014715

Country of ref document: MX

WWE Wipo information: entry into national phase

Ref document number: 2006770516

Country of ref document: EP

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 1020077029917

Country of ref document: KR

NENP Non-entry into the national phase

Ref country code: RU

WWE Wipo information: entry into national phase

Ref document number: 11920891

Country of ref document: US